CRYSTALLINE FORMS OF (1S)-1-[5-({3-[(2-METHYLPYRIDIN-3-YL)OXY]-5-(PYRIDIN-2-YLSULFANYL)PYRIDIN-2-YL}AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL

摘要

The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.